compounding semaglutide fda enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA to Restrict Ingredients Used

Because of the reported positive treatment outcomes, the high prevalence of these disorders in both psychiatric and primary care settings, and the low risk and good tolerability of NAC, the use of NAC as either a monotherapy or an augmentation strategy with conventional psychotropic medications seems to be a reasonable consideration

However, a throughline is the importance of skill building for long-lasting change

Thyroid panel (TSH, Free T4, Free T3) thyroid dysfunction is a major cause of hair loss and should always be ruled out

Subcellular localization of N -acetyl-aspartyl-glutamate, N -acetyl-glutamate and glutathione in brain